Article ; Online: Déjà vu: Stimulating open drug discovery for SARS-CoV-2.
2020 Volume 25, Issue 5, Page(s) 928–941
Abstract: ... by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). There is a strong sense of déjà vu because there are still no ... as active in in vitro assays that are being repurposed in clinical trials. Promising SARS-CoV-2 viral ... antiviral drug discovery approaches for previous outbreaks, that there could still be gaps in our approach ...
| Abstract | In the past decade we have seen two major Ebola virus outbreaks in Africa, the Zika virus in Brazil and the Americas and the current pandemic of coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). There is a strong sense of déjà vu because there are still no effective treatments. In the COVID-19 pandemic, despite being a new virus, there are already drugs suggested as active in in vitro assays that are being repurposed in clinical trials. Promising SARS-CoV-2 viral targets and computational approaches are described and discussed. Here, we propose, based on open antiviral drug discovery approaches for previous outbreaks, that there could still be gaps in our approach to drug discovery. |
|---|---|
| MeSH term(s) | Angiotensin-Converting Enzyme 2 ; Animals ; Antiviral Agents/pharmacology ; Antiviral Agents/therapeutic use ; Betacoronavirus/drug effects ; Betacoronavirus/metabolism ; COVID-19 ; Chlorocebus aethiops ; Computer Simulation ; Coronavirus Infections/drug therapy ; Drug Discovery ; Drug Repositioning ; Hemorrhagic Fever, Ebola/drug therapy ; Humans ; In Vitro Techniques ; Middle East Respiratory Syndrome Coronavirus ; Molecular Docking Simulation ; Pandemics ; Peptidyl-Dipeptidase A/metabolism ; Pneumonia, Viral/drug therapy ; Severe acute respiratory syndrome-related coronavirus ; SARS-CoV-2 ; Severe Acute Respiratory Syndrome/drug therapy ; Spike Glycoprotein, Coronavirus/metabolism ; Vero Cells ; Zika Virus Infection/drug therapy ; COVID-19 Drug Treatment |
| Chemical Substances | Antiviral Agents ; Spike Glycoprotein, Coronavirus ; spike protein, SARS-CoV-2 ; Peptidyl-Dipeptidase A (EC 3.4.15.1) ; ACE2 protein, human (EC 3.4.17.23) ; Angiotensin-Converting Enzyme 2 (EC 3.4.17.23) |
| Keywords | covid19 |
| Language | English |
| Publishing date | 2020-04-19 |
| Publishing country | England |
| Document type | Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Review |
| ZDB-ID | 1324988-5 |
| ISSN | 1878-5832 ; 1359-6446 |
| ISSN (online) | 1878-5832 |
| ISSN | 1359-6446 |
| DOI | 10.1016/j.drudis.2020.03.019 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 4725: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.